Notice of results for the nine months ended 30 September 2015
(Oslo, Norway, 27 October 2015) Bionor Pharma ASA (OSE:BIONOR) will report its financial results for the nine months ended 30 September 2015 on 3 November 2015 at 08:00am CET.
A conference call for analysts and investors will be held on 3 November 2015 at 13:00am CET. David H. Solomon, CEO, and Jens Krøis, CFO, will provide an update on the business.
The call can be accessed by dialing:
Norway: +47 2316 2729
Denmark: +45 38 32 28 69
United Kingdom: +44 20 3427 1914
USA: +1 646 254 3367
Sweden: +46 850 653 937
Participant code: 8070043
A presentation will be available on our website, www.bionorpharma.com, prior to the call.
A webcast of the conference call will be available during and after the event via this link: http://edge.media-server.com/m/p/pv9gko9j
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a possible functional HIV cure. The Company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. Bionor is currently well advanced in the planning of BIOSKILL, a proof-of-concept Phase II clinical trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights of Vacc-4x, i.e., the upside potential from partnering or licensing remain with the Company’s shareholders. Bionor Pharma is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York City, New York. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.
Announcement as PDF